Soleno Therapeutics (SLNO) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
1 Feb, 2026Opening remarks and agenda
The meeting was called to order by the CFO, who introduced the board members, nominees, and key representatives present, including legal counsel and the Inspector of Elections.
The agenda included electing one Class 1 Director, ratifying the appointment of the independent auditor, and approving amendments to the equity incentive plan.
The meeting was conducted virtually, with voting procedures explained and proxies collected via email.
Board and executive committee updates
The board consists of six members divided into three classes, with one Class 1 Director position up for election.
Dr. Andrew Sinclair was nominated for re-election as Class 1 Director, recommended by the Nominating and Corporate Governance Committee.
Shareholder proposals
Stockholders were asked to vote on three proposals: electing a Class 1 Director, ratifying Marcum LLP as independent auditor, and amending the 2014 Equity Incentive Plan.
No additional director nominations were received from stockholders.
Latest events from Soleno Therapeutics
- Strong U.S. launch for new PWS therapy, with rapid uptake and expanding insurance coverage.SLNO
Cantor Global Healthcare Conference 2025 - VYKAT XR rapidly transformed PWS care with strong sales, durable efficacy, and broad access in 2025.SLNO
Corporate presentation - VYKAT XR sees rapid adoption, strong coverage, and expansion plans in rare disease markets.SLNO
TD Cowen 46th Annual Health Care Conference - Profitable 2025 with $190.4M revenue, rapid VYKAT XR adoption, and strong market penetration.SLNO
Q4 2025 - Strong market uptake, stable safety, and robust reimbursement support ongoing growth.SLNO
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - NDA for DCCR accepted with priority review; launch prep and global expansion underway.SLNO
2024 Cantor Global Healthcare Conference - FDA review on track, strong market demand, and launch plans advancing in U.S. and Europe.SLNO
Guggenheim Inaugural Global Healthcare Innovation Conference - Oral therapy for Prader-Willi shows robust efficacy, with regulatory filing expected soon.SLNO
Goldman Sachs 45th Annual Global Healthcare Conference - FDA approves VYKAT XR as first hyperphagia therapy in PWS, launching April 2025.SLNO
FDA Announcement